The Antibody Society
Founded in 2007, The Antibody Society is an international, non-profit trade association serving individuals and organizations involved in antibody-related research and development. The Society’s core structure is composed of Committees, which offer leadership opportunities to members interested in participating in Society activities and initiatives.
The Antibody Society are an authoritative source of information about antibody therapeutics development, which they disseminate via their website, presentations and publications. For example:
- Web Resources pages provide access to publications of the Society’s research and commentary, relevant news about antibody therapeutics development, and information about antibody product candidates undergoing regulatory review and approved products.
- Learning Center provides access to our webinars, including series on Antibody Discovery & Development, Adaptive Immune Receptor Repertoire studies, Antibodies to Watch, and Antibody Reagent Validation.
They also organize Symposia on topics relevant to antibody research and development. As a business association, the Society can engage with government and international agencies such as the World Health Organization to discuss issues of importance to the antibody community.
Further information about The Antibody Society’s Mission and Initiatives can be found here.
Pharma Focus Europe
Pharma Focus Europe is a Bi-annual magazine from Ochre Media. It is the leading Pharma title in digital versions serving the information needs of key executives from the world's leading Pharma providers. Pharma Focus Europe covers important issues and trends shaping the future of the Pharma industry across Europe and rest of the world. It offers dedicated, reliable and accurate coverage of the industry's progress and incisive analysis to help its readers make informed decisions to stay ahead of the competition.
European Biopharmaceutical Review
EBR informs and educates on the latest developments and innovations in drug discovery in the pharma sector. Focusing on research and development in pharma, EBR features discussions on cutting-edge science, including topics such as oncology, cell and gene therapies, biologics and degenerative diseases, allowing contributors to highlight their own most exciting research and analysis, and their potential impacts.
To get in touch, please email either Louise (Media Manager) louise@samedanltd.com or Charlie (Editor) charlie@samedanltd.com.
The Journal of Human Antibodies
IOS Press is an international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in health and life sciences (including neurosciences, medical informatics, cancer research, and rehabilitation). Specifically, publish Human Antibodies an international journal designed to bring together all aspects of human hybridomas and antibody technology, along with factors that modulate host antibody repertoire and effectiveness, such as vaccines, infectious agents, and microbiome." In addition, we offer specialized services that support scientific advancement.
Bioanalysis Zone
Bioanalysis Zone provides bioanalysts with a range of resources, including: the latest bioanalytical news; articles from Bioanalysis; exclusive interviews and commentaries; informative webinars; Spotlights focusing on bioanalytical ‘hot topics’; a business directory; and annual awards to show recognition of outstanding achievements in the field. Our mission is to advance the field of bioanalysis by increasing subject understanding and sharing of knowledge across barriers to unite the bioanalytical community.
Antibodies
Antibodies is an international, peer-reviewed open access journal that provides an advanced forum for scientific publications related to antibodies and antigens.
- High Visibility: Covered by Scopus (Citescore 9.6), ESCI (Web of Science, IF 4.7), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases;
- Rapid Publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 4.9 days (median values for papers published in this journal in the second half of 2023).
- Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates launched in 2013, is designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians/physicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. The Journal’s content includes peer reviewed research, commentaries, news features, discussions, editorials and blogs on topics relevant to a broad international readership. The Journal also offers a knowledge center (called ADC University) offering the latest and most relevant information about Antibody-drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.
International Biopharmaceutical Industry
IBI provides the biopharmaceutical industry with comprehensive coverage of key scientific, technology, regulatory and business topics. The editorial mix of peer-reviewed papers, practical advice on managing bioprocessing and technology, regulatory and business columns, and expert commentary provides comprehensive coverage of upstream and downstream processing, manufacturing operations, regulations, formulation, scale-up/technology transfer, drug delivery, analytical testing and more. We will report on emerging trends, strategies and best practices in the key areas. IBI publishes, Peer Reviewed papers in the form of technical case studies, application notes; topical literature or patent reviews; novel research; or science-based opinion papers. All papers undergo a peer review process by IBI’s Editorial Advisory Board of scientists, managers, directors and consultants.
For further information please visit: www.international-biopharma.com
Contact:
Anthony Stewart
International Media Director
Email: anthony@senglobalcoms.com
Chloe Euripides
Editorial Manager
Email: chloe@senglobalcoms.com
GeneTherapyNet.com
Gene Therapy Net is the web resource for patients and professionals interested in gene therapy. The objectives of Gene Therapy Net are to be the information resource for basic and clinical research in gene therapy, cell therapy, and genetic vaccines, and to serve as a network in the exchange of information and news related to above areas. In addition, Gene Therapy Net provides an overview for sponsors and researchers of the different international regulations and guidelines associated with clinical gene therapy trials. For resources pertaining to regenerative cell therapy and clinical treatment, check out R3 Stem Cell.
SelectScience
At SelectScience® we are accelerating science by connecting scientific communities with trusted solutions. We produce and publish high-quality digital content and deliver content marketing solutions, whilst also informing scientists about the best products and technologies in their field through the power of peer-to-peer recommendation and reviews.
Bio-Equip
www.bio-equip.com was established in the early days of the Internet, in July 1998. Over the last two decades, themed on serving life sciences and serving high quality suppliers, Bio-equip has provided the users in the fields of life sciences, medicine research, biological pharmacy, bio-engineering, modern agriculture, food safety, environmental monitoring, and forensic science with the industrial information in terms of devices and instruments, reagents, consumables, lab animals, cell lines, books, biological R&D service, second-hand instruments, and instrument repairs.
There are two versions, the Chinese version (bio-equip.com) and English version (bio-equip.cn): So far over 30,000 companies have registered as members and provided over 1 million product entries in the Chinese version (www.bio-equip.com); the daily visits exceed over 60,000. The English version (www.bio-equip.cn), established in 2006, is the only English website in this field. Until December 2022, over 1,000 companies from both at home and abroad have registered as members, covering the fields of manufacturing, sale, and agency of instruments/reagents with over 100,000 product entries.
Pharma Tech Outlook
Pharma Tech Outlook is a monthly publication that has been a pioneer in bringing forth real-world solutions, news, product trends, solutions, and many more to subscribers. The unique learn-from-peers approach is creating a difference since the decision-makers are constantly sharing their experience, wisdom and thought leadership with each other. Pharma Tech Outlook has contributors from the most established organizations and institutions who have been presenting their viewpoints using this unique print platform. The magazine has been incorporated by some seasoned industry experts and has been at the forefront of presenting a comprehensive and detailed view of the technology arena. Pharma Tech Outlook aims at contributing to the transformation of innovations into services as well as creating a healthy and productive ecosystem.